These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19138518)

  • 21. Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds.
    Venkatachalam TK; Mao C; Uckun FM
    Bioorg Med Chem; 2004 Aug; 12(15):4275-84. PubMed ID: 15246104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.
    Mugnaini C; Alongi M; Togninelli A; Gevariya H; Brizzi A; Manetti F; Bernardini C; Angeli L; Tafi A; Bellucci L; Corelli F; Massa S; Maga G; Samuele A; Facchini M; Clotet-Codina I; Armand-Ugón M; Esté JA; Botta M
    J Med Chem; 2007 Dec; 50(26):6580-95. PubMed ID: 18052319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
    Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
    J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
    Frey KM; Puleo DE; Spasov KA; Bollini M; Jorgensen WL; Anderson KS
    J Med Chem; 2015 Mar; 58(6):2737-45. PubMed ID: 25700160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural modifications of DAPY analogues with potent anti-HIV-1 activity.
    Feng XQ; Liang YH; Zeng ZS; Chen FE; Balzarini J; Pannecouque C; De Clercq E
    ChemMedChem; 2009 Feb; 4(2):219-24. PubMed ID: 19090525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
    Le Van K; Cauvin C; de Walque S; Georges B; Boland S; Martinelli V; Demonté D; Durant F; Hevesi L; Van Lint C
    J Med Chem; 2009 Jun; 52(12):3636-43. PubMed ID: 19469474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.
    Benjahad A; Oumouch S; Guillemont J; Pasquier E; Mabire D; Andries K; Nguyen CH; Grierson DS
    Bioorg Med Chem Lett; 2007 Feb; 17(3):712-6. PubMed ID: 17157017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase.
    García-Sosa AT; Sild S; Takkis K; Maran U
    J Chem Inf Model; 2011 Oct; 51(10):2595-611. PubMed ID: 21875140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
    Cullen MD; Deng BL; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; Clercq ED; Cushman M
    J Med Chem; 2007 Oct; 50(20):4854-67. PubMed ID: 17803290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Spallarossa A; Cesarini S; Ranise A; Bruno O; Schenone S; La Colla P; Collu G; Sanna G; Secci B; Loddo R
    Eur J Med Chem; 2009 Apr; 44(4):1650-63. PubMed ID: 18954921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and studies of new 2-(coumarin-4-yloxy)-4,6-(substituted)-S-triazine derivatives as potential anti-HIV agents.
    Mahajan DH; Pannecouque C; De Clercq E; Chikhalia KH
    Arch Pharm (Weinheim); 2009 May; 342(5):281-90. PubMed ID: 19415671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
    Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
    Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 4'-C-ethynyl-2',3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosides.
    Siddiqui MA; Hughes SH; Boyer PL; Mitsuya H; Van QN; George C; Sarafinanos SG; Marquez VE
    J Med Chem; 2004 Oct; 47(21):5041-8. PubMed ID: 15456247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
    Regina GL; Coluccia A; Piscitelli F; Bergamini A; Sinistro A; Cavazza A; Maga G; Samuele A; Zanoli S; Novellino E; Artico M; Silvestri R
    J Med Chem; 2007 Oct; 50(20):5034-8. PubMed ID: 17803291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
    Butini S; Brindisi M; Cosconati S; Marinelli L; Borrelli G; Coccone SS; Ramunno A; Campiani G; Novellino E; Zanoli S; Samuele A; Giorgi G; Bergamini A; Di Mattia M; Lalli S; Galletti B; Gemma S; Maga G
    J Med Chem; 2009 Feb; 52(4):1224-8. PubMed ID: 19170521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
    Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
    ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
    Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E
    Eur J Med Chem; 2008 Dec; 43(12):2800-6. PubMed ID: 18242784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
    Xue H; Lu X; Zheng P; Liu L; Han C; Hu J; Liu Z; Ma T; Li Y; Wang L; Chen Z; Liu G
    J Med Chem; 2010 Feb; 53(3):1397-401. PubMed ID: 20050672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and anti-HIV activity of GS-9148 (2'-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor.
    Boojamra CG; Mackman RL; Markevitch DY; Prasad V; Ray AS; Douglas J; Grant D; Kim CU; Cihlar T
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1120-3. PubMed ID: 18164198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
    Rotili D; Samuele A; Tarantino D; Ragno R; Musmuca I; Ballante F; Botta G; Morera L; Pierini M; Cirilli R; Nawrozkij MB; Gonzalez E; Clotet B; Artico M; Esté JA; Maga G; Mai A
    J Med Chem; 2012 Apr; 55(7):3558-62. PubMed ID: 22428851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.